Short Term Rating on ZIOPHARM Oncology Inc (ZIOP)

ZIOPHARM Oncology Inc (ZIOP) : 1 brokerage houses believe that ZIOPHARM Oncology Inc (ZIOP) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ZIOPHARM Oncology Inc (ZIOP). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Hold with a rating of 3.

ZIOPHARM Oncology Inc (ZIOP) stock is expected to deviate a maximum of $9.9 from the average target price of $14 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $21 and the most muted being $7.

Company shares have received an average consensus rating of Hold for the current week


ZIOPHARM Oncology Inc (NASDAQ:ZIOP): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.01 and $5.93 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.07. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.99, notching a gain of 1.01% for the day. The total traded volume was 2,009,721 . The stock had closed at $5.93 on the previous day.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.